Compassionate Use Patient Treated with Matinas MAT2203 Shows Complete Clinical Resolution of Fungal Infection

  Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan and her team delivered an oral presentation earlier today at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen discussing MAT2203’s clinical impact in treating a compassionate use patient suffering from Rhodotorula mucilaginosa (R. mucilaginosa), a rare and opportunistic invasive fungal infection.

https://finance.yahoo.com/news/compassionate-patient-treated-matinas-biopharma-120000746.html